Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SYRS

Syros Pharmaceuticals Inc

Dec 12 • 04:00PM ET

0.2358

Dollar change -0.0091
Percentage change -3.72	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE RGEN IONS CRSP NTLA EDIT FATE SGMO

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.03	Insider Own	35.06%	Shs Outstand	26.83M	Perf Week	-0.25%
Market Cap	6.33M	Forward P/E	-	EPS next Y	-2.05	Insider Trans	-3.83%	Shs Float	17.43M	Perf Month	-91.36%
Income	-97.81M	PEG	-	EPS next Q	-0.69	Inst Own	36.36%	Short Float	12.82%	Perf Quarter	-87.91%
Sales	0.39M	P/S	16.22	EPS this Y	73.32%	Inst Trans	7.62%	Short Ratio	0.27	Perf Half Y	-95.93%
Book/sh	-0.41	P/B	-	EPS next Y	-32.26%	ROA	-84.04%	Short Interest	2.23M	Perf Year	-95.20%
Cash/sh	2.17	P/C	0.11	EPS next 5Y	-	ROE	-776.96%	52W Range	0.18 - 8.17	Perf YTD	-96.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.16%	ROI	-210.27%	52W High	-97.11%	Beta	1.29
Dividend TTM	-	Quick Ratio	2.25	Sales past 5Y	128.79%	Gross Margin	-228.76%	52W Low	28.85%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.25	EPS Y/Y TTM	19.37%	Oper. Margin	-28892.23%	RSI (14)	29.27	Volatility	9.51% 18.70%
Employees	68	Debt/Eq	-	Sales Y/Y TTM	-95.61%	Profit Margin	-25340.67%	Recom	2.50	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	88.66%	Payout	-	Rel Volume	0.24	Prev Close	0.24
Sales Surprise	-100.00%	EPS Surprise	76.34%	Sales Q/Q	-100.00%	Earnings	Oct 31 BMO	Avg Volume	8.28M	Price	0.24
SMA20	-7.51%	SMA50	-83.26%	SMA200	-93.89%	Trades		Volume	2,021,187	Change	-3.72%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-20	Upgrade	H.C. Wainwright	Neutral → Buy	$11 → $15
Sep-22-20	Initiated	Alliance Global Partners	Buy	$18
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Mar-08-19	Resumed	JMP Securities	Mkt Outperform	$18
Feb-14-19	Resumed	Oppenheimer	Outperform	$13
Nov-05-18	Upgrade	ROTH Capital	Neutral → Buy
Mar-13-18	Reiterated	Wedbush	Outperform	$11 → $13
Oct-31-17	Resumed	Piper Jaffray	Overweight	$30
Oct-23-17	Initiated	ROTH Capital	Neutral	$15
Aug-10-17	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Nov-14-24 06:35AM	Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright (TipRanks) -23.37%
Nov-13-24 07:27AM	Syros stock craters after lead cancer therapy flops in Phase III trial (Clinical Trials Arena) -86.85%
Nov-12-24 04:30PM	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression (Business Wire) -15.48%
Nov-01-24 09:00AM	Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com) -10.12%
Oct-31-24 07:30AM	Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
07:08AM	Loading…
Oct-24-24 07:08AM	Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 (Business Wire) -8.00%
Oct-09-24 03:33PM	Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com)
Sep-12-24 07:00PM	Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com) +24.20%
07:00PM	Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) (GuruFocus.com)
Aug-27-24 07:00AM	Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences (Business Wire) -5.99%
Aug-14-24 10:19AM	Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination (Zacks) -15.89%
09:35AM	Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-13-24 09:41AM	Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome (Benzinga) -61.68%
09:13AM	Syros stock craters after Phase II AML trial termination due to inefficacy (Pharmaceutical Technology)
Aug-12-24 04:15PM	Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial (Business Wire)
09:55AM	Loading…
Aug-05-24 09:55AM	Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:30AM	Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Jul-24-24 07:00AM	Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 (Business Wire)
Jul-17-24 11:24AM	Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why (Zacks)
08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-13-24 07:00AM	Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression (Business Wire) +7.41%
May-15-24 03:03AM	Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
01:14AM	Q1 2024 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 10:52AM	SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +7.31%
07:30AM	Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
May-07-24 09:00AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
07:00AM	Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 (Business Wire)
May-01-24 10:01AM	Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-24 09:49AM	Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML (Zacks)
08:30AM	Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Loading…
Apr-09-24 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression (Business Wire) +22.22%
Apr-02-24 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.04% +7.44%
Mar-28-24 10:06AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.39%
Mar-27-24 11:53AM	SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.56%
07:30AM	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Mar-25-24 07:00AM	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial (Business Wire)
Mar-20-24 07:00AM	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 (Business Wire)
Feb-27-24 07:00AM	Syros to Participate in TD Cowen 44th Annual Health Care Conference (Business Wire)
Jan-31-24 04:00PM	3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential (InvestorPlace)
Jan-19-24 10:43AM	Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why (Zacks)
Jan-18-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice (Zacks) -6.09%
Jan-17-24 08:50AM	Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-16-24 12:00PM	What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know (Zacks)
Jan-11-24 08:48AM	Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick (Zacks)
Jan-08-24 07:00AM	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene (Business Wire)
Jan-03-24 11:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals (GuruFocus.com) -9.95%
Dec-19-23 07:27AM	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +30.93%
Dec-07-23 09:44AM	Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene (Zacks) +15.92%
Dec-06-23 07:00AM	Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine (Business Wire) +42.55%
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-21-23 07:30AM	Syros to Participate in Upcoming Investor Conferences (Business Wire)
Nov-15-23 01:08PM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript (Insider Monkey) +11.76%
Nov-14-23 07:30AM	Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-23 07:30AM	Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire) +5.36%
Oct-02-23 08:45AM	Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company (Business Wire) -18.73%
Sep-07-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 09:49PM	Q2 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:05AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Aug-01-23 07:30AM	Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-27-23 06:29AM	The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet (American City Business Journals)
Jul-21-23 05:40PM	Pfizer to end license deal with Syros for blood disorder therapies (Reuters)
Jul-05-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-22-23 08:14PM	Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-08-23 07:30AM	Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference (Business Wire)
Jun-01-23 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-25-23 05:05PM	Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting (Business Wire) -5.06%
08:44AM	One Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \ (Simply Wall St.)
May-13-23 10:15AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 10:08PM	Q1 2023 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +10.29%
08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update (Business Wire)
May-09-23 07:00AM	Syros to Present at JMP Securities 2023 Life Sciences Conference (Business Wire)
May-07-23 08:40PM	ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? (Zacks)
May-03-23 07:30AM	Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (Business Wire)
May-02-23 07:00AM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.95%
Mar-06-23 09:48AM	Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 07:08AM	Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Mar-02-23 10:02PM	Q4 2022 Syros Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:35AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (Business Wire)
Feb-28-23 07:30AM	Syros to Participate in Upcoming Investor Conferences in March (Business Wire)
Feb-23-23 07:30AM	Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 (Business Wire)
Feb-09-23 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.61%
Feb-01-23 09:43AM	Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jan-26-23 07:00AM	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome (Business Wire)
Jan-09-23 07:00AM	Syros Announces Clinical Updates and 2023 Strategic Priorities (Business Wire)
Dec-23-22 04:05PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-16-22 06:47AM	One Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous year (Simply Wall St.) -7.73%
Dec-12-22 07:30AM	Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS (Business Wire) +5.04%
Dec-10-22 10:00AM	Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial (Business Wire)
Dec-05-22 07:00AM	Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 (Business Wire)
Nov-22-22 07:30AM	Syros to Participate at Piper Sandler 34th Annual Healthcare Conference (Business Wire)
Nov-14-22 08:45AM	Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.04%
07:30AM	Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
Nov-07-22 07:30AM	Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (Business Wire)
Nov-04-22 04:30PM	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Richard Young	Director	Dec 10 '24	Proposed Sale	0.23	6,667	1,533		Dec 10 03:01 PM
Simonian Nancy A	Director	Dec 02 '24	Sale	0.27	37,070	10,016	4,000	Dec 04 05:00 PM
Nancy Cole	Director	Dec 02 '24	Proposed Sale	0.27	37,070	10,016		Dec 02 05:07 PM
Simonian Nancy A	Director	Nov 25 '24	Sale	0.27	134,713	35,739	41,070	Nov 27 05:00 PM
Simonian Nancy A	Director	Nov 25 '24	Proposed Sale	0.20	134,713	26,943		Nov 25 05:59 PM
Stephens Kristin	Chief Development Officer	Nov 18 '24	Sale	0.22	36,133	7,949	0	Nov 20 05:00 PM
Roth David	Chief Medical Officer	Nov 18 '24	Sale	0.20	12,099	2,382	0	Nov 20 05:00 PM
Quirk Gerald E	Chief Legal & Compliance Offic	Nov 19 '24	Sale	0.22	46,657	10,321	0	Nov 20 05:00 PM
Chee Conley	President & CEO	Nov 18 '24	Sale	0.20	134,797	26,932	0	Nov 20 05:00 PM
Haas Jason	Chief Financial Officer	Nov 18 '24	Sale	0.21	137,803	28,980	0	Nov 20 05:00 PM
Quirk Gerald E	Officer	Nov 19 '24	Proposed Sale	0.22	46,657	10,323		Nov 19 05:22 PM
Haas Jason	Officer	Nov 18 '24	Proposed Sale	0.23	37,803	8,669		Nov 18 06:00 PM
Roth David	Officer	Nov 18 '24	Proposed Sale	0.20	12,099	2,382		Nov 18 05:42 PM
Stephens Kristin	Officer	Nov 18 '24	Proposed Sale	0.22	36,133	7,949		Nov 18 05:20 PM
Chee Conley	Officer	Nov 18 '24	Proposed Sale	0.20	30,797	6,139		Nov 18 04:45 PM
JASON HAAS	Officer	Nov 18 '24	Proposed Sale	0.20	100,000	20,310		Nov 18 04:18 PM
Chee Conley	Officer	Nov 18 '24	Proposed Sale	0.26	100,000	25,930		Nov 18 12:08 PM
Chee Conley	President & CEO	Sep 11 '24	Buy	1.71	50,000	85,420	122,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 12 '24	Buy	1.68	45,344	76,006	124,552	Sep 12 05:00 PM
Chee Conley	President & CEO	Sep 10 '24	Buy	1.51	50,000	75,260	72,504	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 10 '24	Buy	1.55	35,363	54,788	59,915	Sep 12 05:00 PM
Haas Jason	Chief Financial Officer	Sep 11 '24	Buy	1.58	19,293	30,446	79,208	Sep 12 05:00 PM
Young Richard A	Director	Jun 28 '24	Sale	5.12	34,837	178,365	8,000	Jul 02 04:15 PM
Roth David	Chief Medical Officer	Apr 03 '24	Sale	4.95	10,451	51,732	0	Apr 05 04:30 PM
Roth David	Chief Medical Officer	Apr 02 '24	Sale	4.98	150	747	10,451	Apr 02 04:58 PM
AKKARAJU SRINIVAS	Director	Dec 21 '23	Buy	4.42	904,977	3,999,998	1,786,427	Dec 26 05:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SYRS

Syros Pharmaceuticals Inc

Upgrade your FINVIZ experience